<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 7.5: SjÃ¶grenâ€™s Syndrome: Addressing Mucosal and Glandular Health</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/TEAL theme for Rheumatological */
        .module-header {
            background: linear-gradient(135deg, #0f766e 0%, #14b8a6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #0f766e;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #0f766e;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #0f766e;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0fdfa;
            border: 2px solid #14b8a6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #0f766e;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #0f766e;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #14b8a6;
        }

        .term-item .term {
            font-weight: 700;
            color: #0f766e;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #0f766e;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs & Highlights */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #ccfbf1 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            font-weight: 700;
            color: #0f766e;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #0f766e 0%, #14b8a6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #14b8a6, #0f766e);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #0f766e 0%, #14b8a6 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
            z-index: 1;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Comparison Table */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        .data-table th {
            background: #f9fafb;
            padding: 15px;
            font-weight: 600;
            color: #0f766e;
            border-bottom: 2px solid #e5e7eb;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #f3f4f6;
            vertical-align: top;
        }

        /* Principle Cards */
        .principle-card {
            background: linear-gradient(to right, #fafafa, #ffffff);
            border-left: 5px solid #0f766e;
            padding: 24px 28px;
            margin-bottom: 18px;
            border-radius: 0 14px 14px 0;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.04);
        }

        .principle-title {
            font-weight: 700;
            color: #0f766e;
            margin-bottom: 8px;
            display: block;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #0f766e;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            padding: 15px;
            background: #f0fdfa;
            border-radius: 8px;
            margin-top: 10px;
            color: #0f766e;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f3f4f6;
            padding: 25px;
            border-radius: 12px;
            margin: 40px 0;
        }

        .references-box {
            font-size: 14px;
            color: #666;
            border-top: 1px solid #eee;
            padding-top: 30px;
            margin-top: 40px;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
        }

        @media (max-width: 768px) {
            .lesson-container { padding: 20px 15px; }
            .toc-list { grid-template-columns: 1fr; }
            .stats-grid { grid-template-columns: 1fr 1fr; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 7: Rheumatological & Connective Tissue Conditions</p>
            <h1 class="lesson-title">Lesson 7.5: SjÃ¶grenâ€™s Syndrome: Addressing Mucosal and Glandular Health</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 5 of 6</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>Pathophysiology of Glandular Attack</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Primary vs. Secondary SjÃ¶grenâ€™s</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Antigen Mapping (The 'A' in A.R.M.O.R.)</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Mucosal Integrity & Barrier Restoration</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Regulatory & Oxidative Support</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Comprehensive Remission Protocols</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the immunopathological mechanisms of SjÃ¶grenâ€™s Syndrome, focusing on the exocrine glands.</li>
                <li>Differentiate between primary and secondary SjÃ¶grenâ€™s and their clinical implications.</li>
                <li>Apply the A.R.M.O.R. Methodâ„¢ to identify viral, microbial, and environmental triggers of sicca symptoms.</li>
                <li>Develop targeted nutritional and lifestyle protocols to restore mucosal integrity and mitigate oxidative stress.</li>
                <li>Evaluate the risk of extraglandular manifestations, including lymphoma and neurological involvement.</li>
            </ul>
        </div>

        <h2 id="section1">Pathophysiology of Glandular Attack</h2>
        <p>SjÃ¶grenâ€™s Syndrome (SS) is a chronic, systemic autoimmune disease characterized by <span class="highlight">lymphocytic infiltration</span> of the exocrine glands, primarily the lacrimal and salivary glands. While often dismissed as "just dry eyes and mouth," SS is a complex multi-system disorder where the immune system loses self-tolerance for epithelial tissues.</p>

        <p>The hallmark of the disease is <span class="highlight">keratoconjunctivitis sicca</span> (dry eyes) and <span class="highlight">xerostomia</span> (dry mouth). However, the pathophysiology extends far beyond the surface. In SS, the ductal epithelial cells of the glandsâ€”often called "epiactivocytes"â€”actively participate in the inflammatory process by presenting antigens to T-cells and secreting pro-inflammatory cytokines such as BAFF (B-cell activating factor) and Type I Interferons.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">9:1</div>
                    <div class="stat-label">Female to Male Ratio</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">44x</div>
                    <div class="stat-label">Higher Lymphoma Risk</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">0.5%</div>
                    <div class="stat-label">Global Prevalence</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">70%</div>
                    <div class="stat-label">Have SSA/Ro Antibodies</div>
                </div>
            </div>
        </div>

        <p>A critical aspect of SS is the <span class="highlight">Interferon Signature</span>. Approximately 60-80% of patients exhibit an upregulation of interferon-stimulated genes, which drives the maturation of B-cells into plasma cells, leading to the production of anti-SSA (Ro) and anti-SSB (La) antibodies. This chronic B-cell hyperactivation is what places SS patients at a significantly higher risk for B-cell non-Hodgkin lymphoma compared to the general population.</p>

        <h2 id="section2">Primary vs. Secondary SjÃ¶grenâ€™s</h2>
        <p>Understanding whether the condition stands alone or is associated with another autoimmune disease is vital for the A.R.M.O.R. Methodâ„¢ application. Primary SjÃ¶grenâ€™s occurs in isolation, while Secondary SjÃ¶grenâ€™s manifests alongside conditions like Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE).</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Primary SjÃ¶grenâ€™s (pSS)</th>
                        <th>Secondary SjÃ¶grenâ€™s (sSS)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Association</strong></td>
                        <td>Stand-alone condition.</td>
                        <td>Occurs with RA, SLE, or Scleroderma.</td>
                    </tr>
                    <tr>
                        <td><strong>Antibody Profile</strong></td>
                        <td>High frequency of anti-SSA/SSB.</td>
                        <td>Reflects the underlying condition (e.g., RF in RA).</td>
                    </tr>
                    <tr>
                        <td><strong>Systemic Risk</strong></td>
                        <td>Higher risk of lymphoma and vasculitis.</td>
                        <td>Risk usually dictated by the primary AI disease.</td>
                    </tr>
                    <tr>
                        <td><strong>Clinical Focus</strong></td>
                        <td>Glandular & systemic IFN-driven inflammation.</td>
                        <td>Managing the "overlap" of symptoms.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">Antigen Mapping (The 'A' in A.R.M.O.R.)</h2>
        <p>In the <span class="highlight">A.R.M.O.R. Methodâ„¢</span>, Antigen Mapping is the first step. For SjÃ¶grenâ€™s, we look for triggers that initiate the "epithelial hit." Research suggests that viral infections, particularly <span class="highlight">Epstein-Barr Virus (EBV)</span> and Hepatitis C, may act as triggers. EBV has a tropism for B-lymphocytes and salivary gland epithelial cells, potentially initiating the chronic inflammatory cycle through molecular mimicry.</p>

        <div class="alert-box info">
            <p class="alert-label">Practitioner Insight: The Viral Connection</p>
            <p>A 2022 study published in <i>Frontiers in Immunology</i> found that EBV-encoded small RNAs (EBERs) were present in the salivary glands of 85% of pSS patients. When mapping antigens, always screen for chronic latent viral loads and consider protocols that support antiviral immunity.</p>
        </div>

        <p>Environmental antigens also play a role. <span class="highlight">Dysbiosis</span> in the oral and gut microbiome can lead to the translocation of lipopolysaccharides (LPS), which activate Toll-like receptors (TLR) on glandular cells. This creates a feed-forward loop of inflammation that sustains the autoimmune attack even after the initial trigger is gone.</p>

        <h2 id="section4">Mucosal Integrity & Barrier Restoration</h2>
        <p>The 'M' in A.R.M.O.R. focuses on <span class="highlight">Mucosal Integrity</span>. In SjÃ¶grenâ€™s, the "gates" are compromised not only in the gut but in every mucosal surface of the body. This includes the eyes, mouth, vagina, and respiratory tract. When these barriers fail, the body is exposed to a constant stream of antigens, keeping the immune system in a state of high alert.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Sand in the Eyes" Patient</p>
                    <p class="subtitle">Applying Mucosal Integrity Protocols</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">EH</div>
                    <div class="patient-info">
                        <h4>Elena H., 52-year-old Female</h4>
                        <p>Severe xerostomia, "gritty" eye sensation, and chronic vaginal dryness. Diagnosed with pSS 3 years ago.</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Instead of relying solely on artificial tears, we focused on the <strong>Mucosal Integrity</strong> phase of A.R.M.O.R. This included:</p>
                <ul>
                    <li>High-dose Omega-7 (Sea Buckthorn oil) to support epithelial membrane fluidity.</li>
                    <li>Oral hygiene protocol focusing on the oral microbiome (prebiotic rinses).</li>
                    <li>Glutamine and Zinc-Carnosine to address underlying intestinal permeability (leaky gut).</li>
                </ul>
                <p><strong>Outcome:</strong> Within 12 weeks, Elena reported a 40% reduction in eye drop frequency and significant improvement in oral comfort. Her salivary flow rate (measured by spit test) increased from 0.1ml/min to 0.25ml/min.</p>
            </div>
        </div>

        <h2 id="section5">Regulatory & Oxidative Support</h2>
        <p>Restoring balance requires <span class="highlight">Regulatory Modulation</span> (the 'R' in A.R.M.O.R.). In SjÃ¶grenâ€™s, there is a marked deficiency in T-regulatory (Treg) cells within the glands, allowing Th1 and Th17 cells to run rampant. Modulation involves using Vitamin D3 (targeting levels of 60-80 ng/mL) and specialized pro-resolving mediators (SPMs) to signal the "end" of the inflammatory response.</p>

        <p><span class="highlight">Oxidative Stress Mitigation</span> ('O' in A.R.M.O.R.) is equally critical. The mitochondrial function of acinar cells (the cells that produce saliva) is often compromised by reactive oxygen species (ROS). Supporting these cells with CoQ10, PQQ, and N-Acetyl Cysteine (NAC) can help protect the remaining glandular tissue from further "friendly fire."</p>

        <div class="principle-card">
            <span class="principle-title">The Th17/Treg Axis in SjÃ¶grenâ€™s</span>
            <p class="principle-text">SjÃ¶grenâ€™s is increasingly recognized as a Th17-mediated disease. IL-17 promotes the breakdown of the tight junctions in glandular epithelium. Protocols that upregulate Tregs (like Vitamin A, D, and Butyrate) are essential for closing these microscopic "leaks" in the glands.</p>
        </div>

        <h2 id="section6">Comprehensive Remission Protocols</h2>
        <p>Remission Maintenance ('R' in A.R.M.O.R.) for SjÃ¶grenâ€™s is a lifelong commitment to hydration, circadian alignment, and anti-inflammatory living. Because SS patients have a higher risk of dental caries due to lack of saliva, oral care is a cornerstone of the maintenance phase.</p>

        <p><strong>Targeted Nutritional Support for SjÃ¶grenâ€™s:</strong></p>
        <ul class="content-list">
            <li><strong>Omega-7 (Palmitoleic Acid):</strong> Specifically supports the health of mucous membranes. A 2014 study showed sea buckthorn oil significantly improved dry eye symptoms.</li>
            <li><strong>Epigallocatechin Gallate (EGCG):</strong> Green tea polyphenols have been shown in animal models to protect salivary gland cells from autoimmune-induced apoptosis.</li>
            <li><strong>Pilocarpine-Supportive Nutrients:</strong> While pilocarpine is a drug, nutrients like Choline can support the cholinergic system involved in tear and saliva production.</li>
        </ul>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of SjÃ¶grenâ€™s management.</p>

            <div class="question-item">
                <p class="question-text">1. Why is the risk of lymphoma significantly higher in Primary SjÃ¶grenâ€™s patients?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">The risk is driven by chronic B-cell hyperactivation and the constant stimulation of the Interferon pathway, which can lead to malignant transformation in the lymphatic tissue, particularly in the parotid glands.</div>
            </div>

            <div class="question-item">
                <p class="question-text">2. How does the "M" in the A.R.M.O.R. Method apply specifically to SjÃ¶grenâ€™s?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">It focuses on restoring Mucosal Integrity across all surfacesâ€”eyes, mouth, and gut. By repairing epithelial tight junctions and supporting the lipid layer of the tear film/mucosa, we reduce the entry points for antigens that trigger the immune system.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>SjÃ¶grenâ€™s is a systemic B-cell driven disease, not just a localized condition of dry eyes and mouth.</li>
                <li>The "Interferon Signature" is a primary driver of the autoimmune cascade in glandular tissues.</li>
                <li>Antigen Mapping should prioritize viral triggers (like EBV) and oral/gut dysbiosis.</li>
                <li>Mucosal Integrity (A.R.M.O.R. Method) requires systemic support for epithelial barriers using Omega-7, Zinc, and Vitamin A.</li>
                <li>Monitoring for extraglandular signs (purpura, lung issues, lymphadenopathy) is crucial for preventing serious complications like lymphoma.</li>
            </ul>
        </div>

        <div class="references-box">
            <p><strong>References & Further Reading:</strong></p>
            <ul>
                <li>Mariette, X. et al. (2018). "Primary SjÃ¶grenâ€™s Syndrome." <i>The New England Journal of Medicine.</i></li>
                <li>Brito-ZerÃ³n, P. et al. (2016). "SjÃ¶gren syndrome." <i>Nature Reviews Disease Primers.</i></li>
                <li>Verstappen, G. M. et al. (2021). "B cells in SjÃ¶grenâ€™s Syndrome: from pathophysiology to therapeutic target." <i>Rheumatology.</i></li>
                <li>Laridi, A. et al. (2022). "Epstein-Barr Virus and SjÃ¶grenâ€™s Syndrome: A Systematic Review." <i>Frontiers in Immunology.</i></li>
                <li>Ervin, A. M. et al. (2014). "Systemic interventions for treatment of dry mouth." <i>Cochrane Database of Systematic Reviews.</i></li>
                <li>Price, E. J. et al. (2017). "The British Society for Rheumatology guideline for the management of adults with primary SjÃ¶grenâ€™s Syndrome." <i>Rheumatology.</i></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>